Effect of N-acetyl cysteine (NAC) in treatment of persistent Helicobacter infection

Evaluation of the additive therapeutic effect of N-acetyl cysteine (NAC)on the treatment of persistent Helicobacter pylori (H.pylori) infection

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190326043119N1

Enrollment

126

Registered

2020-02-28

Start date

2018-08-23

Completion date

Unknown

Last updated

2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Persistent helicobacter infection. Certain infectious and parasitic diseases

Interventions

Intervention 1: Intervention group: which used for treatment them standard and NAC we want to compare treatment ratio in both group which take NAC and did not take that we used NAC 600mg bid for 14 d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The patients who refer to shahid Beheshti hospital and Helal e Ahmar clinic who take one episode treatment of H.pylori and did not respond in endoscopy or noninvasive tests such as urease test or stool Ag who we told them persistent h pylori patient

Exclusion criteria

Exclusion criteria: The patients who used chronically NSAID or corticosteroid Have gastric outlet obstruction Pregnancy Renal failure Gastric cancer Precious surgery Use bismuth in first treatment extract of the study

Design outcomes

Primary

Measure	Time frame
Negative response of stool Ag. Timepoint: Stool Ag 4 weeks after treatment. Method of measurement: Stool Ag in labratory.	—

Secondary

Measure	Time frame
Side effects. Timepoint: After 2 weeks treatment. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Farshad Ferydooni

Yasouj University of Medical Sciences

Fagerist2013@gmail.com+98 74 3322 0165

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026